Australia markets close in 4 hours 26 minutes

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
19.97-0.02 (-0.10%)
At close: 04:00PM EST
20.35 +0.38 (+1.90%)
After hours: 04:13PM EST

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
https://castlebiosciences.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full-time employees587

Key executives

NameTitlePayExercisedYear born
Mr. Derek J. MaetzoldFounder, CEO, President & Director1.45M203.3k1962
Mr. Frank StokesCFO & Treasurer849.36k62.36k1970
Ms. Kristen M. Oelschlager R.N.Chief Operating Officer782.7k136.74k1968
Mr. Tobin W. JuvenalChief Commercial Officer782.7k68.94k1960
Camilla ZuckeroVice President of Investor Relations & Corporate AffairsN/AN/AN/A
Ms. Alice Bahner IzzoSenior Vice President of MarketingN/AN/AN/A
Ms. Keli GreenbergVP of Human Resources & Executive Director of Human ResourcesN/AN/AN/A
Dr. Robert W. Cook Ph.D.Senior Vice President of Research & DevelopmentN/AN/A1972
Mr. Bernhard E. SpiessCompany Secretary528.35kN/A1960
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Corporate governance

Castle Biosciences, Inc.’s ISS governance QualityScore as of 1 December 2023 is 9. The pillar scores are Audit: 4; Board: 5; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.